{"filing":{"accession_number":"0001703057-26-000049","cik":"0001703057","ticker":"ABCL","company_name":"AbCellera Biologics Inc.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"abcl-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000049/abcl-20260807.htm"},"events":[{"id":25108,"run_id":22779,"accession_number":"0001703057-26-000049","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"AbCellera announced it will release top-line Phase 2 trial data for ABCL635 on August 10, 2026, and host an investor conference call. This is a material clinical milestone disclosure for a clinical-stage biotech company—Phase 2 trial results are significant operational and strategic events that would affect investor assessment of the company's pipeline progress and prospects. While not a formal earnings release, the announcement of imminent clinical data release is a material operational event distinct from routine administrative disclosures.","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":25857,"accession_number":"0001703057-26-000049","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"AbCellera announced it will release top-line Phase 2 trial data for ABCL635 on August 10, 2026, and host an investor conference call. This is a material clinical milestone disclosure for a clinical-stage biotech company—Phase 2 trial results are significant operational and strategic events that would affect investor assessment of the company's pipeline progress and prospects. While not a formal earnings release, the announcement of imminent clinical data release is a material operational event distinct from routine administrative disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T00:27:41.297062+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25857,"accession_number":"0001703057-26-000049","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"AbCellera announced it will release top-line Phase 2 trial data for ABCL635 on August 10, 2026, and host an investor conference call. This is a material clinical milestone disclosure for a clinical-stage biotech company—Phase 2 trial results are significant operational and strategic events that would affect investor assessment of the company's pipeline progress and prospects. While not a formal earnings release, the announcement of imminent clinical data release is a material operational event distinct from routine administrative disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T00:27:41.297062+00:00","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-08-07"}]}